Advertisement

Elevated triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China

  • 3 Accesses

Abstract

Purpose

Previous studies revealed that high serum uric acid (SUA) levels correlated with increased triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio. However, evidence is lacking regarding whether TG/HDL-C is an independent risk factor or just a simple marker of hyperuricemia. We aimed to investigate the relationship between TG/HDL-C and the risk of hyperuricemia in Chinese population.

Methods

This retrospective cohort study involved 15,198 subjects (43.14 ± 13.13 years, 54.9% men) who were free of hyperuricemia at baseline. The association between TG/HDL-C and the risk of hyperuricemia, in the total sample and stratified by subgroups, was examined by multiple logistic regression analyses.

Results

During 4 years follow-up, hyperuricemia occurred in 2365 (15.6%) participants. The cumulative incidence of hyperuricemia was significantly elevated with increasing TG/HDL-C quartiles (5.9, 10.8, 18.4, and 27.5%, respectively). After multivariate adjustment, the odds ratio for hyperuricemia in the highest compared with the lowest quartile of TG/HDL-C was 1.80 (95% confidence interval [CI] 1.49, 2.18), and each SD increment of TG/HDL-C ratio caused a 10% additional risk for hyperuricemia. Moreover, subgroup analyses showed that the association between TG/HDL-C and the risk of hyperuricemia was more pronounced in women and normal-weight adults. The results were consistent when analyses were restricted to participants without metabolic syndrome.

Conclusions

TG/HDL-C ratio was positively related to the risk of hyperuricemia in Chinese population, particularly in women and normal-weight individuals. These findings suggested the potential of TG/HDL-C ratio to serve as an independent risk indicator in the prevention of hyperuricemia.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    T. Bardin, P. Richette, Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 15(1), 123 (2017)

  2. 2.

    A.U.A. Kumar, L.D. Browne, X. Li, F. Adeeb, F. Perez-Ruiz, A.D. Fraser, A.G. Stack, Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: a cohort study. PLoS ONE 13(5), e0198197 (2018)

  3. 3.

    M. Chen-Xu, C. Yokose, S.K. Rai, M.H. Pillinger, H.K. Choi, Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007–2016. Arthritis Rheumatol. 71(6), 991–999 (2019)

  4. 4.

    R. Liu, C. Han, D. Wu, X. Xia, J. Gu, H. Guan, Z. Shan, W. Teng, Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis. BioMed. Res. Int. 2015, 762820 (2015)

  5. 5.

    Z. Miao, C. Li, Y. Chen, S. Zhao, Y. Wang, Z. Wang, X. Chen, F. Xu, F. Wang, R. Sun, J. Hu, W. Song, S. Yan, C.Y. Wang, Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J. Rheumatol. 35(9), 1859–1864 (2008)

  6. 6.

    J.A. Singh, S.G. Reddy, J. Kundukulam, Risk factors for gout and prevention: a systematic review of the literature. Curr. Opin. Rheumatol. 23(2), 192–202 (2011)

  7. 7.

    H. Wang, H. Zhang, L. Sun, W. Guo, Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases. Am. J. Transl. Res. 10(9), 2749–2763 (2018)

  8. 8.

    T. Wang, Y. Bi, M. Xu, Y. Huang, Y. Xu, X. Li, W. Wang, G. Ning, Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese. Endocrine 40(1), 109–116 (2011)

  9. 9.

    K. Wijarnpreecha, P. Panjawatanan, N. Lekuthai, C. Thongprayoon, W. Cheungpasitporn, P. Ungprasert, Hyperuricaemia and risk of nonalcoholic fatty liver disease: a meta-analysis. Liver Int 37(6), 906–918 (2017)

  10. 10.

    Y. Xie, P. Xu, K. Liu, S. Lin, M. Wang, T. Tian, C. Dai, Y. Deng, N. Li, Q. Hao, L. Zhou, Z. Dai, Hyperuricemia and gout are associated with cancer incidence and mortality: a meta-analysis based on cohort studies. J. Cell. Physiol. 234(8), 14364–14376 (2019)

  11. 11.

    T.C. Peng, C.C. Wang, T.W. Kao, J.Y. Chan, Y.H. Yang, Y.W. Chang, W.L. Chen, Relationship between hyperuricemia and lipid profiles in US adults. BioMed. Res. Int. 2015, 127596 (2015)

  12. 12.

    T. Keenan, M.J. Blaha, K. Nasir, M.G. Silverman, R. Tota-Maharaj, J.A. Carvalho, R.D. Conceicao, R.S. Blumenthal, R.D. Santos, Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am. J. Cardiol. 110(12), 1787–1792 (2012)

  13. 13.

    M.J. Stelmach, N. Wasilewska, L.I. Wicklund-Liland, A. Wasilewska, Blood lipid profile and BMI-Z-score in adolescents with hyperuricemia. Ir. J. Med. Sci. 184(2), 463–468 (2015)

  14. 14.

    J. Vekic, Z. Jelic-Ivanovic, V. Spasojevic-Kalimanovska, L. Memon, A. Zeljkovic, N. Bogavac-Stanojevic, S. Spasic, High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. Atherosclerosis 203(1), 236–242 (2009)

  15. 15.

    G.M. Reaven, The kidney: an unwilling accomplice in syndrome X. Am. J. Kidney Dis. 30(6), 928–931 (1997)

  16. 16.

    E. Bonora, B. Capaldo, P.C. Perin, S. Del Prato, G. De Mattia, L. Frittitta, S. Frontoni, F. Leonetti, L. Luzi, G. Marchesini, M.A. Marini, A. Natali, G. Paolisso, P.M. Piatti, A. Pujia, A. Solini, R. Vettor, R.C. Bonadonna, Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutr. Metab. Cardiovasc. Dis. 18(9), 624–631 (2008)

  17. 17.

    M.Dobiasova, J.Frohlich, The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL). Clin. Biochem. 34(7), 583–588 (2001)

  18. 18.

    D. Lin, Y. Qi, C. Huang, M. Wu, C. Wang, F. Li, C. Yang, L. Yan, M. Ren, K. Sun, Associations of lipid parameters with insulin resistance and diabetes: a population-based study. Clin. Nutr. 37(4), 1423–1429 (2018)

  19. 19.

    B.T. Palmisano, L. Zhu, J.M. Stafford, Role of estrogens in the regulation of liver lipid metabolism. Adv. Exp. Med. Biol. 1043, 227–256 (2017)

  20. 20.

    H. Dai, W. Wang, R. Chen, Z. Chen, Y. Lu, H. Yuan, Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr. Metab. 14, 49 (2017)

  21. 21.

    H. Dai, W. Wang, X. Tang, R. Chen, Z. Chen, Y. Lu, H. Yuan, Association between homocysteine and non-alcoholic fatty liver disease in Chinese adults: a cross-sectional study. Nutr. J. 15(1), 102 (2016)

  22. 22.

    Y. Lu, M. Lu, H. Dai, P. Yang, J. Smith-Gagen, R. Miao, H. Zhong, R. Chen, X. Liu, Z. Huang, H. Yuan, Lifestyle and risk of hypertension: follow-up of a young pre-hypertensive cohort. Int. J. Med. Sci. 12(7), 605–612 (2015)

  23. 23.

    Y.C. Ma, L. Zuo, J.H. Chen, Q. Luo, X.Q. Yu, Y. Li, J.S. Xu, S.M. Huang, L.N. Wang, W. Huang, M. Wang, G.B. Xu, H.Y. Wang, Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J. Am. Soc. Nephrol. 17(10), 2937–2944 (2006)

  24. 24.

    World Health Orgnization, Physical status: the use and interpretation of ant hropometry. Report of a WHO Expert Committee. World Health Organ. Technical Report Series no. 854, 1–452 (1995)

  25. 25.

    C. Lenfant, A.V. Chobanian, D.W. Jones, E.J. Roccella, Seventh report of the joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): resetting the hypertension sails. Hypertension 41(6), 1178–1179 (2003)

  26. 26.

    P.H. Marathe, H.X. Gao, K.L. Close, American diabetes association standards of medical care in diabetes 2017. J. Diabetes 9(4), 320–324 (2017)

  27. 27.

    K.G. Alberti, R.H. Eckel, S.M. Grundy, P.Z. Zimmet, J.I. Cleeman, K.A. Donato, J.C. Fruchart, W.P. James, C.M. Loria, S.C. Smith Jr., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640–1645 (2009)

  28. 28.

    T. Bardin, Hyperuricemia starts at 360 micromoles (6 mg/dL). Jt. Bone Spine 82(3), 141–143 (2015)

  29. 29.

    G. Desideri, G. Castaldo, A. Lombardi, M. Mussap, A. Testa, R. Pontremoli, L. Punzi, C. Borghi, Is it time to revise the normal range of serum uric acid levels? Eur. Rev. Med. Pharm. Sci. 18(9), 1295–1306 (2014)

  30. 30.

    Y. Zhang, F. Wei, C. Chen, C. Cai, K. Zhang, N. Sun, J. Tian, W. Shi, M. Zhang, Y. Zang, J. Song, Y. He, J. Feng, Q. Zhou, M. Li, P. Bai, S. Feng, W.D. Li, Higher triglyceride level predicts hyperuricemia: a prospective study of 6-year follow-up. J. Clin. Lipidol. 12(1), 185–192 (2018)

  31. 31.

    A.S. Bomback, V.K. Derebail, D.A. Shoham, C.A. Anderson, L.M. Steffen, W.D. Rosamond, A.V. Kshirsagar, Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int. 77(7), 609–616 (2010)

  32. 32.

    Q.W. Deng, S. Li, H. Wang, L. Lei, H.Q. Zhang, Z.T. Gu, F.L. Xing, F.L. Yan, The short-term prognostic value of the triglyceride-to-high-density lipoprotein cholesterol ratio in acute ischemic stroke. Aging Dis. 9(3), 498–506 (2018)

  33. 33.

    Y.L. Wang, W.P. Koh, M. Talaei, J.M. Yuan, A. Pan, Association between the ratio of triglyceride to high-density lipoprotein cholesterol and incident type 2 diabetes in Singapore Chinese men and women. J. Diabetes 9(7), 689–698 (2017)

  34. 34.

    C.I. Ho, J.Y. Chen, S.Y. Chen, Y.W. Tsai, Y.M. Weng, Y.C. Tsao, W.C. Li, Relationship between TG/HDL-C ratio and metabolic syndrome risk factors with chronic kidney disease in healthy adult population. Clin. Nutr. 34(5), 874–880 (2015)

  35. 35.

    Y. Fukuda, Y. Hashimoto, M. Hamaguchi, T. Fukuda, N. Nakamura, A. Ohbora, T. Kato, T. Kojima, M. Fukui, Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver: a population-based cohort study. Liver Int. 36(5), 713–720 (2016)

  36. 36.

    D.Ozalp Kizilay, S. Sen, B. Ersoy, Associations between serum uric acid concentrations and cardiometabolic risk and renal injury in obese and overweight children. J. Clin. Res Pediatr. Endocrinol. 11(3), 262–269 (2019)

  37. 37.

    K. Chaudhary, K. Malhotra, J. Sowers, A. Aroor, Uric acid - key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 3(3), 208–220 (2013)

  38. 38.

    S.P. Juraschek, L.C. Kovell, E.R. Miller, A.C. Gelber, Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. PLoS ONE 8(2), e56546 (2013)

  39. 39.

    F. Matsuura, S. Yamashita, T. Nakamura, M. Nishida, S. Nozaki, T. Funahashi, Y. Matsuzawa, Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 47(8), 929–933 (1998)

  40. 40.

    T. Balasubramanian, Uric acid or 1-methyl uric acid in the urinary bladder increases serum glucose, insulin, true triglyceride, and total cholesterol levels in Wistar rats. TheScientificWorldJournal 3, 930–936 (2003)

  41. 41.

    K. Kawachi, H. Kataoka, S. Manabe, T. Mochizuki, K. Nitta, Low HDL cholesterol as a predictor of chronic kidney disease progression: a cross-classification approach and matched cohort analysis. Heart Vessels 34(9), 1440–1455 (2019)

  42. 42.

    F. Wang, J. Zheng, P. Ye, L. Luo, Y. Bai, R. Xu, L. Sheng, T. Xiao, H. Wu, Association of high-density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population. PLoS ONE 8(11), e79738 (2013)

  43. 43.

    A.F. Wright, I. Rudan, N.D. Hastie, H. Campbell, A ‘complexity’ of urate transporters. Kidney Int. 78(5), 446–452 (2010)

  44. 44.

    A. Enomoto, H. Kimura, A. Chairoungdua, Y. Shigeta, P. Jutabha, S.H. Cha, M. Hosoyamada, M. Takeda, T. Sekine, T. Igarashi, H. Matsuo, Y. Kikuchi, T. Oda, K. Ichida, T. Hosoya, K. Shimokata, T. Niwa, Y. Kanai, H. Endou, Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417(6887), 447–452 (2002)

  45. 45.

    E. Muscelli, A. Natali, S. Bianchi, R. Bigazzi, A.Q. Galvan, A.M. Sironi, S. Frascerra, D. Ciociaro, E. Ferrannini, Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am. J. Hypertension 9(8), 746–752 (1996)

  46. 46.

    F. Perez-Ruiz, M.A. Aniel-Quiroga, A.M. Herrero-Beites, S.P. Chinchilla, G.G. Erauskin, T. Merriman, Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. Rheumatol. Int. 35(9), 1519–1524 (2015)

  47. 47.

    P. Bjornstad, R.H. Eckel, Pathogenesis of lipid disorders in insulin resistance: a brief review. Curr. Diabetes Rep. 18(12), 127 (2018)

  48. 48.

    Y. Kim, J. Kang, G.T. Kim, Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin. Rheumatol. 37(9), 2529–2538 (2018)

  49. 49.

    G.E. Thottam, S. Krasnokutsky, M.H. Pillinger, Gout and metabolic syndrome: a tangled web. Curr. Rheumatol. Rep. 19(10), 60 (2017)

  50. 50.

    G. Derosa, P. Maffioli, Ž. Reiner, L.E. Simental-Mendía, A. Sahebkar, Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs 76(9), 947–956 (2016)

  51. 51.

    G. Derosa, P. Maffioli, A. Sahebkar, Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol. Res. 102, 63–70 (2015)

  52. 52.

    S. Tsunoda, K. Kamide, J. Minami, Y. Kawano, Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am. J. Hypertens. 15(8), 697–701 (2002)

  53. 53.

    D.N. Kiortsis, T.D. Filippatos, M.S. Elisaf, The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab. 31(1), 15–22 (2005)

  54. 54.

    A. Kottgen, E. Albrecht, A. Teumer, V. Vitart, J. Krumsiek, C. Hundertmark, G. Pistis, D. Ruggiero, C.M. O’Seaghdha, T. Haller, Q. Yang, T. Tanaka, A.D. Johnson, Z. Kutalik, A.V. Smith, J. Shi et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat. Genet. 45(2), 145–154 (2013)

  55. 55.

    A. Bedir, M. Topbas, F. Tanyeri, M. Alvur, N. Arik, Leptin might be a regulator of serum uric acid concentrations in humans. Jpn. Heart J. 44(4), 527–536 (2003)

  56. 56.

    D. Gasevic, J. Frohlich, G.B. Mancini, S.A. Lear, The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort. Metabolism. 61(4), 583–589 (2012)

  57. 57.

    T. Du, G. Yuan, M. Zhang, X. Zhou, X. Sun, X. Yu, Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc. Diabetol. 13, 146 (2014)

  58. 58.

    S.S. Yu, D.C. Castillo, A.B. Courville, A.E. Sumner, The triglyceride paradox in people of African descent. Metab. Syndr. Relat. Disord. 10(2), 77–82 (2012)

Download references

Acknowledgements

We gratefully acknowledge all the participants in this study along with the clinical staff of the Third Xiangya Hospital for their assistance in collecting and examining the biochemical samples.

Funding

This study was funded by the National Key Technology Research and Development Program (No. 2016YFC0900802), and the Postgraduate Innovation Project of Central South University (No. 2014zzts089).

Author contributions

All authors were responsible for drafting the manuscript and revising it critically for constructive intellectual content. All authors approved the version to be published.

Author information

Correspondence to Hong Yuan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consents were obtained from all individual participants included in the study.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, X., Wu, Q., Chen, Z. et al. Elevated triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China. Endocrine (2020) doi:10.1007/s12020-019-02176-5

Download citation

Keywords

  • Hyperuricemia
  • Triglyceride
  • High-density lipoprotein cholesterol
  • Insulin resistance